N
Nervonik
The company's mission is to develop a new generation of implantable devices that can modulate the nervous system to treat a variety of conditions, including chronic pain, epilepsy, and parkinson's…
About Nervonik
Nervonik Inc. is an innovative startup currently operating in stealth mode, which means it is keeping a low profile while developing its technology. The company has created a groundbreaking, miniaturized neuromodulation device designed for therapeutic use. Neuromodulation involves altering nerve activity through targeted delivery of electrical stimulation or chemical agents to specific neurological sites in the body. This technology can be used to treat a variety of medical conditions, such as chronic pain, epilepsy, and depression.
Nervonik's primary clients are likely to be healthcare providers, including hospitals, clinics, and specialized medical practitioners who treat neurological disorders. The market it operates in is the medical device industry, specifically focusing on neuromodulation therapies. This is a rapidly growing sector due to increasing demand for advanced treatment options for neurological conditions.
The business model of Nervonik Inc. revolves around the development, manufacturing, and sale of its neuromodulation devices. The company makes money by selling these devices to healthcare providers and potentially through partnerships or licensing agreements with larger medical device companies. Additionally, Nervonik may generate revenue through ongoing service and maintenance contracts for their devices.
In summary, Nervonik Inc. is poised to make a significant impact in the medical device industry with its innovative neuromodulation technology, targeting healthcare providers who treat neurological conditions.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2021
- Headquarters
- Los Angeles, United States
- Employees
- 13
- Open positions
- 1
- Dealroom signal
- 92.9/100
- Industry
- Health, Semiconductors
- Sub-industry
- Medical Devices
- Sector
- Health Tech & Medtech, Neurology, Neuromodulation and Neurostimulation, Spinout, DT and LS, science-based
- Technology
- Hardware, Deep Tech
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | Apr 2026 | $53M | $210M | U.S. Venture Partners · ShangBay Capital · Foothill Ventures · Lumira Ventures | ↗ |
| SERIES AOther financing | Mar 2025 | $13M | $52M | Correlation Ventures · U.S. Venture Partners · Foothill Ventures | ↗ |
Growth signals
Latest recorded traffic for Nervonik is 1.2K monthly website visits, up 300% over the last three months. Nervonik's team grew 18.2% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A7 investors entered at this stage
U.S. Venture Partners
Correlation Ventures
Foothill Ventures
Amzak Health
ShangBay Capital
Lumira Ventures
Elevage Medical Technologies
Other known investors1 additional known investor
University of California, Los Angeles
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Nervonik on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Nervonik’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.